This study is a single-center, single-arm, prospective clinical trial designed to evaluate the efficacy of local excision followed by postoperative chemoradiotherapy in patients with early-stage low/ultra-low rectal cancer. The study plans to enroll 60 patients with T1-2N0M0 low/ultra-low rectal cancer.
Age ≥18 years, regardless of gender
ECOG performance status 0-1
Biopsy-proven rectal adenocarcinoma
Distal margin of primary tumor ≤8 cm from anal verge
Failure to meet the above inclusion criteria
Patients refusing to sign informed consent
Impaired cognitive function or psychiatric disorders
Patients deemed ineligible by investigators